This website uses only technical or equivalent cookies.
For more information click here.

Machine perfusion in organ transplantation

Special Issue 1 - April 2023 - Machine perfusion in organ transplantation



Key words: kidney, preservation, normothermic machine perfusion
Submission Date: 2022-10-14
Publication Date: 2022-10-20


Normothermic machine perfusion (NMP) has been introduced into transplantation to improve the outcomes of kidneys from marginal donors. This review focuses on the application of NMP detailing the clinical evidence and examining the underlying mechanistic actions. It then explores the evidence for more prolonged periods of NMP and modifications to the protocols. There are only a handful of clinical studies reporting the outcomes of NMP on early renal allograft function. All of the studies used an end period of NMP approach in conjunction with hypothermic preservation techniques. All validated the safety and feasibility of NMP and several reported improved early graft function. Although NMP restores oxidative phosphorylation to support active metabolism and replenish cellular adenosine triphosphate (ATP), inflammatory and immune processes are also activated. This is in response to the period of ischaemia prior to NMP but may also be exacerbated by the perfusion conditions. Removing the inflammatory mediators during NMP, altering conditions or extending the NMP time to minimise ischaemic injury may be beneficial for future application. NMP is a promising new technology in kidney transplantation. Ongoing clinical studies and further development of NMP will determine the benefit of this technology in the coming years.


Kidneys from donation after circulatory death (DCD) and extended criteria donors (ECD) are routinely used in deceased donor kidney transplantation 1-3. However, they are susceptible to delayed graft function (DGF) and more likely to be rejected for transplantation due to donor factors or concerns about their quality 1-6. Furthermore, limited access to theatre due to the growing burden on health services can extend the hypothermic preservation period beyond an acceptable duration, increasing the likelihood of discard 7.

The anoxic environment during hypothermic preservation results in the gradual depletion of adenosine triphosphate (ATP). Maintaining an organ below 10℃ slows this process, but over time this leads to the build-up of toxic substances resulting in irreversible cellular injury 8. Kidneys from older donors are less likely to recover from significant ischaemic injury 3. Furthermore, DCD kidneys incur additional warm ischaemic injury which results in a higher likelihood of DGF or the possibility of irreversible damage resulting in primary non-function 3,4,9.

Preserving organs at a normothermic temperature as an alternative or adjunct to hypothermic preservation may help to improve graft outcomes and increase organ utilisation 10. Ex-vivo normothermic machine perfusion (NMP) involves the circulation of an oxygenated perfusate through the kidney at a near-normal or normal body temperature and normal mean arterial pressure 10. In most cases banked red cells are added as an oxygen carrier and various nutrients, amino acids/electrolytes and supplements added to support cellular metabolism and replenish ATP 10. The evidence for NMP in clinical practice is limited to a small number of case series and several case reports 11-25. One randomised controlled trial (RCT) has recently been completed (results not yet published) 26. All of the studies have used a short period of NMP at the recipient centre following hypothermic preservation.

NMP can also be used to assess viability and as a platform for the administration of therapies directly to the kidney to aid regeneration and repair. These topics have been reviewed in several recent publications 27-33.

This review focuses on the application of NMP in kidney transplantation, detailing the clinical evidence and examining the underlying mechanistic actions. It then explores the experimental evidence for more prolonged periods of NMP and modifications to the protocol and highlights the future clinical trials.


The first clinical application of NMP was reported in 2011 using an adapted paediatric cardiac bypass system 11. The kidney was perfused for 35 minutes after a period of static cold storage (SCS) using a red cell and Ringer’s based solution. The recipient of the ECD kidney had slow graft function but remained dialysis independent. A series of 1 h NMP in 18 ECD kidneys using the same protocol was reported in 2013 12. The results were extremely encouraging with rates of DGF, defined as the requirement for dialysis within the first 7 days post-transplant, of 5.6% compared to 36.2% in a historical control group of 47 matched SCS kidneys. Graft and patient survival were similar at 12 months 12.

In 2019, Minor et al published the first case of controlled rewarming (COR) and NMP using a cell-free solution in a kidney from an ECD 15. After 12.5h of SCS the kidney was gradually rewarmed from 8°C to 35°C over a period of 90 minutes followed by 30 minutes of NMP at 35°C before transplantation. The kidney was perfused with STEEN solution diluted with Ringer’s solution and oxygenated via a membrane oxygenator with 100% oxygen on the Kidney Assist device (XVIVO). The kidney had immediate graft function. The group have since reported the outcome of 6 COR ECD kidneys and compared them to 6 SCS matched controls 16. Creatinine clearance on day 7 post-transplant was 66 ml/min in the COR kidneys compared to 27 ml/min in the cold stored kidneys and the DGF rate was 0 vs 33% in the control kidneys. The estimated glomerular filtration rate (eGFR) at 3 months was significantly higher in the COR kidneys (70 vs 45 ml/min; p = 0.023) 16.

In 2021, the Rotterdam group published the results of a series of 11 NMP kidneys from ECDs over the age of 65 years 13. After hypothermic machine perfusion (HMP), kidneys were perfused for 2 h using a red-cell based solution at 37°C on the Kidney Assist device (XVIVO) with 100% oxygen. The rate of DGF was not significantly different in NMP kidneys compared to in a historical control group of 53 mostly HMP kidneys (36 vs 53%; p = 0.320) 13. There was no difference in eGFR at 3 months or in graft and patient survival at 12 months. There were also no significant differences when pairs of kidneys from the same donor (n = 8) were allocated to NMP or HMP 13.

In 2022, the Toronto group published a series of 13 NMP kidneys from donation after brain death (DBD) (n = 6) and DCD (n = 7) donors 14. These were compared to a series of HMP kidneys from both DCD and DBD donors. Kidneys were perfused using an adapted paediatric cardiac bypass system with STEEN solution and 400 ml of red cells at 37°C. The median perfusion time was 171 minutes (range 44-272 minutes). There were no complications or recipient infections and all of the perfusion cultures were negative. The rate of DGF was similar between groups: 30.8% in the NMP kidneys and 38.5% in the control. Serum creatinine and eGFR up to 12 months post-transplant were similar between the groups 14.

A UK multicentre RCT comparing 1 h NMP (n = 143) with SCS (n = 147) in DCD kidneys has just been completed and the results are due to be published later this year 26. Each of the reported studies uses different protocols and technologies, therefore it is difficult to establish the optimal conditions for and duration of NMP. There is a growing body of research examining the molecular effects of NMP which may guide future protocols.


The overarching goal of NMP is to replenish ATP and restore cellular homeostasis 33. NMP conditions are designed to support metabolism and provide an environment that is protective 34. A common feature of NMP is the use of red cells, either banked units or fresh blood that has been filtered to remove the white cells and platelets 10. This is to minimise inflammation and neutrophil infiltration, prevent platelet adhesion and the formation of thrombi to promote perfusion and recovery 34.

A number of recent studies have used molecular techniques such as RNA sequencing or proteomic approaches to examine the mechanistic effects of NMP. In a series of cortical biopsies from non-transplanted human kidneys undergoing 1 or 2 h NMP after SCS, Ferdinand et al. 35 found a significant upregulation of oxidative phosphorylation (OXPHOS) genes after NMP. OXPHOS is a key pathway required to generate ATP, with potential benefits for cell viability and restoration of cellular homeostasis. However, the upregulation of OXPHOS was accompanied by a significant upregulation of immune and inflammatory processes. Tumour necrosis factor α (TNFα) signalling via nuclear factor kappa B (NFκB) had the largest increase but interleukin 1β (IL1β) and the neutrophil-recruiting chemokine (C-X-C motif) ligand 8 (CXCL8) and CXCL2 were also significantly upregulated. String analysis of the top 50 upregulated genes showed clusters of four main nodes: IL8 and neutrophil recruiting chemokines, inflammasome associated genes, NFκB signalling and transcriptional regulation. To examine the impact of the inflammatory and immune response the same group examined the gene expression in a series of 33 NMP kidneys that were transplanted 35. Kidneys with a lower expression of OXPHOS pathways and enhanced upregulation of inflammatory cytokines had more prolonged DGF compared to those with immediate graft function or just 1 day of DGF 35.

Inflammation is a defensive immune response to facilitate tissue repair 36. When oxygen and circulation are re-introduced after a period of ischaemia, membrane bound receptors such as Toll-like receptors (TLRs), c-type lectin receptors and cytoplasmic nod-like receptors are stimulated and identify damage-associated molecular patterns (DAMPs) released by injured cells 36. This activates the innate immune system stimulating an acute inflammatory response with the secretion of cytokines and chemokines. During NMP, levels of inflammatory cytokines in the circulating perfusate were found to increase throughout perfusion and may further drive the inflammatory response 35,37.

The re-introduction of oxygen also causes the production of reactive oxygen species (ROS), which cause damage to tissue membranes, DNA, lipids and proteins via apoptotic pathways 36. One of the most important sources of ROS in ischaemia reperfusion injury after transplantation is from the respiratory chain at the mitochondrial site 38,39. Depletion of ATP and reduction of the electron carrier pool during ischaemia causes succinate to accumulate. At reperfusion succinate serves as an electron store and is rapidly re-oxidized by reverse electron transport at complex I 39. This reverse action is accompanied by the generation of superoxide anion radicals. Another source of ROS is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that is present in a variety of cells including endothelial cells 36. ROS are also a key signalling molecule for inflammation 36.

In a similar model and protocol to the previously described study using 1 h NMP after SCS, Hameed et al also found significant upregulation of IL1β, CXCL2 and TNFα in a small series of non-transplanted human kidneys 40. However, pathways promoting cell survival and proliferation were also upregulated suggesting a beneficial effect. Compared to the SCS paired kidney, renal function and blood flow were improved during a reperfusion phase with whole blood. Kidneys also had reduced levels of apoptosis, complement activation and oxidative stress compared to SCS kidneys 40.

It is likely that the inflammatory response during NMP is driven in part by the ischaemic injury acquired during SCS. Nonetheless, the perfusion conditions may also have an underlying effect. During storage the deformability and surface charge of banked red cells decreases and the fragility and aggregability increases 41. The heat generated by the perfusion pump, contact with artificial surfaces, gravity assisted drainage and shear stress are among the factors that can cause haemolysis and the release of free heme into the circulating perfusate during NMP 42. Free heme is highly toxic and can induce oxidative stress and inflammation 42. Hosgood et al. found high levels of free heme in banked red cells before NMP 43. Older units of red cells had higher levels of free heme compared to younger units and levels increased significantly over 1 h of perfusion. Although, high levels of free heme had no association with renal perfusion parameters, there was a significant upregulation of genes associated with apoptosis, inflammatory cytokines, chemokines and oxidative stress after NMP 43. No direct correlation could be made; however, free heme may have been a contributing factor and could have a greater impact if longer durations of NMP were performed.

It has also recently been observed that during SCS fibrinogen accumulates within the tubular epithelium 44. When NMP commences, this triggers the intravascular release of fibrinogen which causes red cell aggregation and microvascular plugging. This reduces blood flow and stimulates inflammation within the kidney during NMP. DiRito et al demonstrated that these microvasculature obstructions could be cleared with the addition of tissue plasminogen activator and plasminogen 44. This reduced intrarenal resistance, levels of IL-6 and intercellular adhesion molecule 1 (ICAM-1) and tubular cell injury.


Removing inflammatory mediators from the circulation during NMP may help to reduce the inflammatory response. Haemoadsorber filters remove molecules within a range of 10-50 kDa and have been used to treat sepsis, severe respiratory syndrome and the inflammatory response induced by COVID-19 45-47. In a porcine NMP model the haemoadsorber reduced inflammation and improved renal blood flow 37. When incorporated into the NMP circuit in a study using non-transplanted human kidneys, the haemoadsorber significantly removed a range of cytokines from the circulating perfusate 35. Transcriptional analyses demonstrated a 50% reduction in the number of upregulated genes after 4h NMP compared to the paired kidney perfused on a circuit without the haemoadsorber filter 35. There was a significant downregulation of NLR family pyrin domain containing 3 (NLRP3) inflammasome activating genes such as IL1β, NLRP3, CASP1 and neutrophil recruiting chemokines. The haemoadsorber filter also increased OXPHOS and fatty acid metabolism pathways, demonstrating improved energy metabolism. Lower levels of inflammation and enhanced metabolism suggest improved function post-transplant 35. However, the benefits of removing circulating cytokines from the perfusate have not yet to be tested in clinical practice.

The abrupt change in temperature from hypothermia to normothermia can trigger dysfunction in respiratory control and cause cellular injury 38. As described in the clinical study, COR over 90 minutes of perfusion after SCS preserves better metabolic efficiency compared to abrupt rewarming 15,16. Several studies by Minor et al describe benefits from COR including improved mitochondrial efficiency, improved oxygen consumption and tubular reabsorption, better glomerular function and lower levels of aspartate aminotransferase (AST) after reperfusion 48,49.


It may be beneficial to maintain kidneys under NMP conditions for longer periods to minimise the effects of ischaemic injury. Weissenbacher et al. demonstrated the capacity to preserve human kidneys for up to 24 h or 48 h with a red cell-based solution 50,51. A unique feature of the system to maintain a physiological environment was the recirculation of urine into the perfusate during NMP. Replacing high volumes of urine with a crystalloid solution can result in elevated levels of sodium and abnormal acid-base balance. Urine recirculation enabled kidneys to be perfused for longer with normal acid-base homeostasis. Proteomic profiling by mass spectrometry revealed that urine recirculation was associated with a reduction in DAMPs and an increase in proteins involved in anion transport to maintain pH 52. Without urine recirculation, DAMPs, proteins involved in succinate metabolism and vasoconstriction were upregulated. Furthermore, kidneys could not be perfused for more than 7-8 h 50.

Selzner et al. have published a series of experimental studies using a porcine autotransplant model to examine the effects of more prolonged periods of normothermic ex-vivo kidney perfusion (NEVKP) 53-59. Kidneys with 30 minutes warm ischaemia followed by 8 or 16 h NEVKP had improved graft function post-transplant compared to SCS or 1 h NMP 57,58. McEvoy et al found that proteins involved in key metabolic pathways including fatty acid β-oxidation, the tricarboxylic acid cycle and oxidative phosphorylation were upregulated during 8 h of NEVKP 59. They identified members of the peroxisome proliferator-activated receptors (PPAR) family including PPARA, PPARD and RXRA as upstream regulators.

Urbanellis et al performed transcriptional profiling using microarrays in a similar model on samples taken on day 3 post-transplant 60. NEVKP kidneys were compared to kidneys that were transplanted immediately with no preservation interval and kidneys that were cold stored. NEVKP kidneys had comparable levels of renal function on post-operative day 3 to kidneys without preservation. Fatty acid metabolism used in the generation of ATP by proximal tubular epithelial cells, genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, amino acid synthesis and ATPase binding were all significantly upregulated. Pathways relating to small molecule transport, interferon signalling and chemokine signalling, binding and chemotaxis were enriched in NEVKP indicating recovery from ischaemic injury 60. Furthermore, they noted that uromodulin expression was higher after NEVKP. Uromodulin is produced by tubular epithelial cells and is abundant in normal kidneys. It protects against ischaemia reperfusion injury to regulate the innate immune response in the kidney and is proposed as a biomarker of tubular health 60. The experimental evidence suggests that performing NMP for longer periods is favourable. Weissenbacher et al. found that after 6 h of NMP kidneys with urine recirculation were metabolically more active in the subsequent 18 h period of NMP, suggesting a better recovery of metabolism 52. Nonetheless, it is challenging to carry out long periods of NMP in clinical practice. Portable systems and significant resources are required to transport kidneys using NMP between donor and recipient centres.

Alternatively, the COR technique may rival the necessity for prolonged NMP. Von Horn et al recently investigated the effect of COR compared to continuous NMP for 8 h or 8 h SCS 48. Porcine kidneys with 30 minutes warm ischaemia and 6 h SCS underwent COR for 2 h. Kidneys were auto-transplanted and animals recovered for 7 days. Renal function was significantly improved in the COR and NMP kidneys compared to SCS kidneys and was equally as good as continuous NMP 48. COR kidneys had less tenascin C expression in the tissue compared with SCS kidneys indicating reduced proinflammatory regulation 48.


There are a number of ongoing and new clinical trials registered in the clinical trials databases (Tab. I). Several of these trials are examining the effects of longer periods of NMP using newly developed NMP systems. The new OrganOX Metra K system is a portable device designed to maintain kidneys under NMP conditions for prolonged periods. An ongoing study using the OrganOX Metra K and the urine recirculation protocol is examining the effects of NMP for periods of up to 24 h. Other protocols include a comparison between NMP and HMP.


NMP is a promising new technology in kidney transplantation. At present the clinical evidence is sparse and limited to performing a short end ischaemic period of NMP after hypothermic preservation. There is insufficient evidence to draw any conclusions on the impact on graft function or graft survival. However, most importantly, the safety and feasibility of NMP has been established.

There are some limitations to performing a short end period of NMP. Although NMP has beneficial effects, with upregulation in the expression of genes that promote the generation of energy, there is also an induction of proinflammatory genes which may be harmful. Furthermore, by performing NMP for 1-2 h there may not be enough time for recovery or repair mechanisms to be instigated. The condition of these kidneys may be improved by removing inflammatory cytokines from the circulating perfusate using the haemoadsorber filter or using the COR protocol to better protect the mitochondrial reducing ROS production. Prolonged NMP may have greater potential to facilitate repair. In the coming years, ongoing clinical studies and the further development of NMP kidney systems will determine the benefit of NMP on early graft function.



Conflict of interest statement

The Authors declare no conflict of interest.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author contributions

SAH: wrote and reviewed the manuscript; MLN: co-wrote and reviewed the manuscript.

Ethical consideration

Not applicable.

Figures and tables

Title Registration number Trial Status Intervention
1 Investigation of the safety and feasibility of preservation of kidneys for up to 24 hours at normal body temperature prior to transplant (Oxford, UK) ISRCTN13292277 Single group Recruiting n = 36 NMP up to 24 h
2 Normothermic machine perfusion: an additional value for kidney transplant outcomes? (Rotterdam, Netherlands) NCT04882254 Randomised 1:1 NMP vs HMP Recruiting n = 80 NMP 2 h
3 Normothermic machine perfusion versus static cold storage in human kidney transplantation (Germany) NCT05031052 Randomised 1:1 NMP vs SCS Not recruiting n = 194 End NMP 4 h DBD kidneys
4 Prolonged ex-vivo normothermic machine perfusion for kidney regeneration (Groningen, Netherlands) NCT04693325 Single group Recruiting n =18 Up to 6 h NMP DCD kidneys
5 The feasibility and safety of normothermic ex-vivo kidney perfusion (Toronto, Canada) NCT03136848 Single group Unknown n = 25 NMP 4-10 h
6 Ex-vivo normothermic perfusion in kidney transplantation (Eber Medical Technology) NCT05175885 Non-randomised NMP vs SCS or HMP Not yet recruiting n = 100 NMP
Table I. Registered clinical trials assessing the effects of NMP in kidney transplantation.


  1. Rijkse E, Ceuppens S, Qi H. Implementation of donation after circulatory death kidney transplantation can safely enlarge the donor pool: a systematic review and meta-analysis. Int J Surg. 2021;92. doi:
  2. Manyalich M, Nelson H, Delmonico F. The need and opportunity for donation after circulatory death worldwide. Curr Opin Organ Transplant. 2018;23:136-141. doi:
  3. Summers D, Watson C, Pettigrew G. Kidney donation after circulatory death (DCD): state of the art. Kidney Int. 2015;88:241-249. doi:
  4. Liu L, Cheng K, Huang J. Effect of long cold ischemia time of kidneys from aged donors on prognosis of kidney transplantation. Ann Transplant. 2021;26. doi:
  5. Lentine K, Smith J, Hart A. OPTN/SRTR 2020 Annual Data Report: kidney. Am J Transplant. 2022;22:21-136. doi:
  6. Villanego F, Vigara L, Cazorla J. Evaluation of expanded criteria donors using the kidney donor profile index and the preimplantation renal biopsy. Transpl Int. 2022;35. doi:
  7. Patel K, Nath J, Hodson J. Outcomes of donation after circulatory death kidneys undergoing hypothermic machine perfusion following static cold storage: a UK population-based cohort study. Am J Transplant. 2018;18:1408-1414. doi:
  8. McAnulty J. Hypothermic organ preservation by static storage methods: current status and a view to the future. Cryobiology. 2010;60:S13-S19. doi:
  9. Barreda Monteoliva P, Redondo-Pachón D, Miñambres GE. Kidney transplant outcome of expanded criteria donors after circulatory death. Nefrologia (Engl Ed). Published online 2021. doi:
  10. Elliott T, Nicholson M, Hosgood S. Normothermic kidney perfusion: an overview of protocols and strategies. Am J Transplant. 2021;21:1382-1390. doi:
  11. Hosgood S, Nicholson M. First in man renal transplantation after ex-vivo normothermic perfusion. Transplantation. 2011;92:735-738. doi:
  12. Nicholson M, Hosgood S. Renal transplantation after ex-vivo normothermic perfusion: the first clinical study. Am J Transplant. 2013;13:1246-1252. doi:
  13. Rijkse E, de Jonge J, Kimenai H. Safety and feasibility of 2 h of normothermic machine perfusion of donor kidneys in the Eurotransplant Senior Program. BJS Open. 2021;5. doi:
  14. Mazilescu L, Urbanellis P, Kim S. Normothermic ex-vivo kidney perfusion for human kidney transplantation: first North American results. Transplantation. Published online 2022. doi:
  15. Minor T, von Horn C, Gallinat A. First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation. Am J Transplant. 2020;20:1192-1195. doi:
  16. Zlatev H, von Horn C, Kaths M. Clinical use of controlled oxygenated rewarming of kidney grafts prior to transplantation by ex-vivo machine perfusion. A pilot study. Eur J Clin Invest. 2022;52. doi:
  17. Chandak P, Phillips B, Uwechue R. Dissemination of a novel organ perfusion technique: ex-vivo normothermic perfusion of deceased donor kidneys. Artif Organs. 2019;43:e308-e319. doi:
  18. Hosgood S, Thompson E, Moore T. Normothermic machine perfusion for the assessment and transplantation of declined human kidneys from donation after circulatory death donors. Br J Surg. 2018;105:388-394. doi:
  19. Leighton P, Hosgood S, Butler A. Use of a double-J stent during ex-vivo normothermic machine perfusion of human kidneys. Am J Transplant. 2020;20:1754-1755. doi:
  20. Georgiades F, Hosgood S, Butler A. Use of ex-vivo normothermic machine perfusion after normothermic regional perfusion to salvage a poorly perfused DCD kidney. Am J Transplant. 2019;19:3415-3419. doi:
  21. Pearson R, Wubetu J, Jackson A. Living donor kidney transplant following nephrectomy for renal artery stenosis with arterial reconstruction and viability assessment using ex-vivo normothermic perfusion. BMJ Case Rep. 2021;14. doi:
  22. Pearson R, Asher J, Jackson A. Viability assessment and utilization of declined donor kidneys with rhabdomyolysis using ex-vivo normothermic perfusion without preimplantation biopsy. Am J Transplant. 2021;21:1317-1321. doi:
  23. Nicholson M, Hosgood S. Pre-operative assessment of renal transplant ureteric blood supply using ex-vivo normothermic perfusion. Transplantation. 2015;99. doi:
  24. Hosgood S, Saeb-Parsy K, Hamed M. successful transplantation of human kidneys deemed untransplantable but resuscitated by ex-vivo normothermic machine perfusion. Am J Transplant. 2016;16:3282-3285. doi:
  25. Hosgood S, Nicholson M. The first clinical case of intermediate ex-vivo normothermic perfusion in renal transplantation. Am J Transplant. 2014;14:1690-1692. doi:
  26. Hosgood S, Saeb-Parsy K, Wilson C. Protocol of a randomised controlled, open-label trial of ex-vivo normothermic perfusion versus static cold storage in donation after circulatory death renal transplantation. BMJ Open. 2017;7. doi:
  27. Verstraeten L, Jochmans I. Sense and sensibilities of organ perfusion as a kidney and liver viability assessment platform. Transpl Int. 2022;35. doi:
  28. Warmuzińska N, Łuczykowski K, Bojko B. A review of current and emerging trends in donor graft-quality assessment techniques. J Clin Med. 2022;11. doi:
  29. Radajewska A, Krzywonos-Zawadzka A, Bil-Lula I. Recent methods of kidney storage and therapeutic possibilities of transplant kidney. Biomedicines. 2022;10. doi:
  30. Zulpaite R, Miknevicius P, Leber B. Ex-vivo kidney machine perfusion: therapeutic potential. Front Med (Lausanne). 2021;8. doi:
  31. Hosgood S, Brown R, Nicholson M. Advances in kidney preservation techniques and their application in clinical practice. Transplantation. 2021;105:e202-e214. doi:
  32. Hamelink T, Ogurlu B, De Beule J. Renal normothermic machine perfusion: the road toward clinical implementation of a promising pretransplant organ assessment tool. Transplantation. 2022;106:268-279. doi:
  33. Bellini M, Tortorici F, Amabile M. Assessing kidney graft viability and its cells metabolism during machine perfusion. Int J Mol Sci. 2021;22. doi:
  34. Arykbaeva A, de Vries D, Doppenberg J. Metabolic needs of the kidney graft undergoing normothermic machine perfusion. Kidney Int. 2021;100:301-310. doi:
  35. Ferdinand J, Hosgood S, Moore T. Cytokine absorption during human kidney perfusion reduces delayed graft function-associated inflammatory gene signature. Am J Transplant. 2021;21:2188-2199. doi:
  36. Mittal M, Siddiqui M, Tran K. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126-1167. doi:
  37. Hosgood S, Moore T, Kleverlaan T. Haemoadsorption reduces the inflammatory response and improves blood flow during ex-vivo renal perfusion in an experimental model. J Transl Med. 2017;15. doi:
  38. Minor T, von Horn C. Rewarming injury after cold preservation. Int J Mol Sci. 2019;20. doi:
  39. Beach T, Prag H, Pala L. Targeting succinate dehydrogenase with malonate ester prodrugs decreases renal ischemia reperfusion injury. Redox Biol. 2020;36. doi:
  40. Hameed A, Lu D, Patrick E. Brief normothermic machine perfusion rejuvenates discarded human kidneys. Transplant Direct. 2019;5. doi:
  41. McMahon T. Red blood cell deformability, vasoactive mediators, and adhesion. Front Physiol. 2019;10. doi:
  42. Tan Z, Besser M, Anderson S. Pulsatile versus nonpulsatile flow during cardiopulmonary bypass: extent of hemolysis and clinical significance. ASAIO J. 2020;66:1025-1030. doi:
  43. Hosgood S, Elliott T, Jordan N. The effects of free heme on functional and molecular changes during ex-vivo normothermic machine perfusion of human kidneys. Front Immunol. 2022;13. doi:
  44. DiRito J, Hosgood S, Reschke M. Lysis of cold-storage-induced microvascular obstructions for ex-vivo revitalization of marginal human kidneys. Am J Transplant. 2021;21:161-173. doi:
  45. Köhler T, Schwier E, Praxenthaler J. Therapeutic modulation of the host defense by hemoadsorption with CytoSorb® – basics, indications and perspectives – a scoping review. Int J Mol Sci. 2021;22. doi:
  46. Hakemi M, Nassiri A, Nobakht A. Benefit of hemoadsorption therapy in patients suffering sepsis-associated acute kidney injury: a case series. Blood Purif. Published online 2022:1-8. doi:
  47. Alavi Darazam I, Kazempour M, Pourhoseingholi M. Efficacy of hemoperfusion in severe and critical cases of COVID-19. Blood Purif. Published online 2022:1-9. doi:
  48. von Horn C, Zlatev H, Kaths M. Controlled oxygenated rewarming compensates for cold storage-induced dysfunction in kidney grafts. Transplantation. 2022;106:973-978. doi:
  49. Zlatev H, von Horn C, Minor T. Preservation of mitochondrial coupling and renal function by controlled oxygenated rewarming of porcine kidney grafts. Biomolecules. 2021;11. doi:
  50. Weissenbacher A, Lo Faro L, Boubriak O. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am J Transplant. 2019;19:178-192. doi:
  51. Weissenbacher A, Messner F, Gasteiger S. Forty-eight hours of normothermic kidney preservation applying urine recirculation. Artif Organs. 2022;46:710-714. doi:
  52. Weissenbacher A, Huang H, Surik T. Urine recirculation prolongs normothermic kidney perfusion via more optimal metabolic homeostasis – a proteomics study. Am J Transplant. 2021;21:1740-1753. doi:
  53. Mazilescu L, Urbanellis P, Kaths M. Prolonged normothermic ex-vivo kidney perfusion is superior to cold nonoxygenated and oxygenated machine perfusion for the preservation of DCD porcine kidney grafts. Transplant Direct. 2021;7. doi:
  54. Urbanellis P, Mazilescu L, Kollmann D. Prolonged warm ischemia time leads to severe renal dysfunction of donation-after-cardiac death kidney grafts. Sci Rep. 2021;11. doi:
  55. Urbanellis P, Hamar M, Kaths J. Normothermic ex-vivo kidney perfusion improves early DCD graft function compared with hypothermic machine perfusion and static cold storage. Transplantation. 2020;104:947-955. doi:
  56. Hamar M, Urbanellis P, Kaths M. Normothermic ex-vivo kidney perfusion reduces warm ischemic injury of porcine kidney grafts retrieved after circulatory death. Transplantation. 2018;102:1262-1270. doi:
  57. Kaths J, Echeverri J, Linares I. Normothermic ex-vivo kidney perfusion following static cold storage-brief, intermediate, or prolonged perfusion for optimal renal graft reconditioning?. Am J Transplant. 2017;17:2580-2590. doi:
  58. Kaths J, Cen J, Chun Y. Continuous normothermic ex-vivo kidney perfusion is superior to brief normothermic perfusion following static cold storage in donation after circulatory death pig kidney transplantation. Am J Transplant. 2017;17:957-969. doi:
  59. McEvoy C, Clotet-Freixas S, Tokar T. Normothermic ex-vivo kidney perfusion in a porcine auto-transplantation model preserves the expression of key mitochondrial proteins: an unbiased proteomics analysis. Mol Cell Proteomics. 2021;20. doi:
  60. Urbanellis P, McEvoy C, Škrtić M. Transcriptome analysis of kidney grafts subjected to normothermic ex-vivo perfusion demonstrates an enrichment of mitochondrial metabolism genes. Transplant Direct. 2021;7. doi:



Sarah A. Hosgood - Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK

Michael L. Nicholson - Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK

How to Cite
  • Abstract viewed - 754 times
  • PDF downloaded - 126 times